RPE65 and Leber congenital amaurosis: The approval of voretigene neparvovec for the treatment of retinal pigment epithelium-specific 65 (RPE65)-associated LCA has strengthened the application of AAV-mediated retinal gene therapies as they transition from proof of concept to clinical treatments.